Medications for Gaucher Disease
6 results
Cerdelga (eliglustat)
(eliglustat)Genzyme Corporation
Usage: CERDELGA is indicated for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are CYP2D6 extensive, intermediate, or poor metabolizers. It is not recommended for ultra-rapid metabolizers or patients with indeterminate CYP2D6 genotypes due to potential inadequate therapeutic effect.
Cerezyme (imiglucerase)
(IMIGLUCERASE)Genzyme Corporation
Usage: Cerezyme is indicated for the treatment of adults and pediatric patients aged 2 years and older with Type 1 Gaucher disease, addressing conditions such as anemia, thrombocytopenia, bone disease, and hepatomegaly or splenomegaly.
Elelyso (taliglucerase alfa)
(Taliglucerase alfa)Pfizer Laboratories Div Pfizer Inc
Usage: ELELYSO is indicated for the treatment of Type 1 Gaucher disease in patients aged 4 years and older with a confirmed diagnosis.
Miglustat (miglustat)
(miglustat)CoTherix, Inc.
Usage: Miglustat is indicated as monotherapy for adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not an option due to allergy, hypersensitivity, or poor venous access.
Vpriv (velaglucerase alfa)
(velaglucerase alfa)Takeda Pharmaceuticals America, Inc.
Usage: VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type 1 Gaucher disease.
Zavesca (miglustat)
(miglustat)Actelion Pharmaceuticals US, Inc.
Usage: ZAVESCA is indicated as a standalone treatment for adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not viable due to factors like allergy, hypersensitivity, or inadequate venous access.